Author: Publisher:
ISBN:
Category : Biotechnology
Languages : en
Pages : 32
Book Description
Singapore Biotechnology, a Growing Industry
Author: Starting Up an Industry
Author: Emma ArmitagePublisher:
ISBN:
Category : Biotechnology industries
Languages : en
Pages : 188
Book Description
In 2000, Singapore's government launched a strategy to establish the biotechnology industry as one of the pillars of its future economic growth. This targeted 'causative' process involved support policies, the creation and strengthening of research bodies, construction of a purpose-built bio-hub, attraction of foreign drug companies, and investment in local start-ups. These organisations, support factors, and the networks between them constitute Singapore's national innovation system as it relates to biotech. Fourteen years on, Singapore's causative approach has resulted in job creation and increased per capita income. It has also seen many of biotechnology's top multinational corporations base a section of their operations within the country. However, the country's innovation system has yet to produce a community of Singapore-started small and medium sized dedicated biotechnology firms, referred to here as SDBFs. Small and medium sized firms are key drivers of innovation in the biotechnology sector and their presence is necessary to create a sustainable cluster. There is considerable interest from academia and industry in understanding and learning from the development of Singapore's local firms under its national innovation system. Hence, the purpose of this thesis is to study how Singapore's national innovation system has affected its biotechnology sector, with particular focus on its effect on SDBFs. This thesis used mixed methods to investigate the research question. The quantitative approach involved the construction of a database of Singapore-started biotechnology firms and their characteristics. The qualitative method utilised semi-structured interviews with 16 professionals in Singapore's biotechnology sector. The findings pointed to several key conclusions. Firstly, participants felt that increases in the availability of commercialisable patents, risk-comfortable venture capitalists, and entrepreneurial individuals are necessary factors to promote the emergence and success of start-up firms. Findings also showed that the majority of SDBFs studied are located outside of purpose-built hubs, which participants suggested might influence their business model. In addition, SDBFs appeared to be moving into the relatively 'lower risk' sub-sector of medical devices. Overall, a critical mass of firms, human capital, and support factors emerged as a state that Singapore must reach for the industry to thrive. This research builds on the body of work concerning the national innovation system framework and Singapore's biotechnology industry. It acts as a snapshot in time of SDBFs and the perspectives of a sample of individuals in the biotechnology industry. The data gathered here outlines the effect Singapore's national innovation system has had on the industry and emphasises the importance of the critical mass concept. This can be used to inform future policies and as an indicator of the characteristics of the SDBF level of the industry.
Biotech Industry
Author: Bryan BergeronPublisher: John Wiley & Sons
ISBN: 0471647578
Category : Business & Economics
Languages : en
Pages : 384
Book Description
"The biotech industry is a complex, rapidly evolving, and critical industry. The industry holds great commercial and societal promise, but it is also filled with hype, confusion, and risks. Bergeron and Chan do a remarkable job of providing a sweeping insightful, and probing assessment of the current state and likely evolution of this global industry. This book is essential reading for the executive who desires a thorough understanding of this business and its potential."--John P. Glasser, Vice President and Chief Information Offers, Partners Healthcare System, Inc. "Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."--Michael A. Greeley, Managing General Partner, IDG Ventures. An in-depth examination of the growth and financing of the biotechnology industry worldwide Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where it's being applied, and where money and intellectual capital are flowing. Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives Eos and other senior-level managers an understanding of Asia's pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.
Securing Growth in Hong Kong and Singapore Biotech Industry
Author: Shawn HsiaPublisher:
ISBN:
Category : Biotechnology industries
Languages : en
Pages : 138
Book Description
The Singapore Biotechnology Industry
Author: Jie WangBetting on Biotech
Author: Joseph WongPublisher: Cornell University Press
ISBN: 0801463378
Category : Political Science
Languages : en
Pages : 217
Book Description
After World War II, several late-developing countries registered astonishingly high growth rates under strong state direction, making use of smart investment strategies, turnkey factories, and reverse-engineering, and taking advantage of the postwar global economic boom. Among these economic miracles were postwar Japan and, in the 1960s and 1970s, the so-called Asian Tigers—Singapore, South Korea, and Taiwan—whose experiences epitomized the analytic category of the "developmental state." In Betting on Biotech, Joseph Wong examines the emerging biotechnology sector in each of these three industrial dynamos. They have invested billions of dollars in biotech industries since the 1990s, but commercial blockbusters and commensurate profits have not followed. Industrial upgrading at the cutting edge of technological innovation is vastly different from the dynamics of earlier practices in established industries. The profound uncertainties of life-science-based industries such as biotech have forced these nations to confront a new logic of industry development, one in which past strategies of picking and making winners have given way to a new strategy of throwing resources at what remain very long shots. Betting on Biotech illuminates a new political economy of industrial technology innovation in places where one would reasonably expect tremendous potential—yet where billion-dollar bets in biotech continue to teeter on the brink of spectacular failure.
An Assessment of the Medical Biotechnology Industry in Singapore
Author: Diana Guan Boon ChiaFrom Breakthrough to Blockbuster
Author: Donald L. DrakemanPublisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241
Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Betting on Biotech
Author: Joseph WongPublisher: Cornell University Press
ISBN: 0801463386
Category : Political Science
Languages : en
Pages : 217
Book Description
After World War II, several late-developing countries registered astonishingly high growth rates under strong state direction, making use of smart investment strategies, turnkey factories, and reverse-engineering, and taking advantage of the postwar global economic boom. Among these economic miracles were postwar Japan and, in the 1960s and 1970s, the so-called Asian Tigers—Singapore, South Korea, and Taiwan—whose experiences epitomized the analytic category of the "developmental state." In Betting on Biotech, Joseph Wong examines the emerging biotechnology sector in each of these three industrial dynamos. They have invested billions of dollars in biotech industries since the 1990s, but commercial blockbusters and commensurate profits have not followed. Industrial upgrading at the cutting edge of technological innovation is vastly different from the dynamics of earlier practices in established industries. The profound uncertainties of life-science-based industries such as biotech have forced these nations to confront a new logic of industry development, one in which past strategies of picking and making winners have given way to a new strategy of throwing resources at what remain very long shots. Betting on Biotech illuminates a new political economy of industrial technology innovation in places where one would reasonably expect tremendous potential—yet where billion-dollar bets in biotech continue to teeter on the brink of spectacular failure.
Biotechnology - Around the World
Author: Ajit PandyaPublisher: CreateSpace
ISBN: 9781517056841
Category :
Languages : en
Pages : 100
Book Description
With the slew of biotechnology related events and news of late, the common man's curiosity and interest in a simple technical analysis of biotechnology have been sufficiently whetted. The ball was set in motion with the completion of the Human Genome Project in 2000. This was followed concurrently by other technological and on-the-ground developments such as the commercialization and cultivation of Genetically Modified (GM) crops. Global Scenario: According to a research report by Ernst & Young titled Beyond Borders 2002, the global biotech industry comprised of 4,284 companies (622 public; 3,6662 private) in 25 nations. The 622 public companies have generated revenues of $35 bn, spent $16 bn on R&D and employed more than 188,000 people. US biotech companies roughly account for 70% of the total global revenues of biotech industry but other regions are growing at a fast pace too. Biotech sectors in Europe, Canada and the Asia-Pacific region have experienced significant growth in the number of companies due to advancements in technologies, which are mining their way from research labs to full fledged commercialized enterprises. It was estimated that by 2005, the European biotech market could double to more than $100 bn. This growth has led the companies and experienced investors to look beyond the borders of their own countries in search of promising technologies, talented people and new markets. Biotech is an emerging sector in Asia-Pacific, which is experiencing considerable expansion in countries such as Australia, china, India and Singapore with the presence of around 500 biotech companies. Indian Biotech Industry: In the global biotech market, the current share of India is just about 2%; however, the future seems very bright as biotechnology is a fast emerging sector in the country. The Association of Biotech Led Enterprises (ABLE) pegs the Indian biotech market, including biosuppliers, Rs. 23.05 bn in the year 2002-03. The market size is estimated to be Rs. 18.30 bn if biosuppliers are excluded. The market is divided among the Bioindustrial, Bioservice, Bioagriculgture, Bioinformatics and Biosuppliers. Shantha Biotech was the first in India to launch an indigenous recombinant product called Shanvac-B (hepatitis-B vaccine) in 1997. Other players in this are included Biocon Bharat biotech, Bharat serums, Biological E Hlffkine Bio-Pharmaceutical, Panacea, Pfizer, Serum Institute of India, SmithKline Beecham and Wokhardt.